Standout Papers

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remittin... 2012 2026 2016 2021 868
  1. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial (2012)
    Jeffrey Cohen, Alasdair Coles et al. The Lancet

Immediate Impact

2 from Science/Nature 71 standout
Sub-graph 1 of 22

Citing Papers

Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis
2025 Standout
STING orchestrates the neuronal inflammatory stress response in multiple sclerosis
2024 Standout
3 intermediate papers

Works of M. Stojanovic being referenced

Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS
2016
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
2012 Standout

Author Peers

Author Last Decade Papers Cites
M. Stojanovic 806 55 358 268 18 1.0k
Amy Pace 966 23 535 289 15 1.2k
Suzanne Gazda 609 54 269 223 13 993
Pierangelo Barbero 601 57 395 252 31 916
A. Guseo 678 48 315 272 24 980
William H. Stuart 968 24 335 520 18 1.3k
Peter Alping 751 13 337 311 13 913
Becky Parks 664 68 338 200 30 1.1k
E. Verdun 820 19 426 256 24 1.1k
Bettina Stubinski 1113 13 493 306 15 1.3k
C. H. Polman 782 11 371 249 12 896

All Works

Loading papers...

Rankless by CCL
2026